Last updated: February 13, 2026
What Is the Drug Identified by NDC 21922-0052?
NDC 21922-0052 refers to Otezla (apremilast), manufactured by Amgen. Otezla is an oral phosphodiesterase 4 (PDE4) inhibitor approved for treating psoriasis, psoriatic arthritis, and Behçet’s disease.
Current Market Landscape
1. Indications and Market Size
- Approved indications: Plaque psoriasis, psoriatic arthritis, Behçet’s disease.
- Global psoriasis market expected to reach USD 15.4 billion by 2025 (Grand View Research).
- Psoriatic arthritis segment projected at USD 2.9 billion by 2025.
2. Competitive Positioning
- Otezla faces competition from biologics (Humira, Stelara, Cosentyx) and other oral agents, such as systemic immunomodulators.
- Its oral route offers convenience versus injectable biologics but is challenged by the efficacy gap with biologics.
3. Market Penetration and Growth Drivers
- Increasing prevalence of psoriasis and psoriatic arthritis.
- Growing acceptance of oral treatments.
- Expanded labels and off-label use drive revenue.
| 4. Key Firms and Market Shares |
Company |
Leading Drugs |
Estimated Market Share (2023) |
| Amgen |
Otezla |
30% |
| AbbVie |
Humira, Skyrizi |
35% |
| Johnson & Johnson |
Stelara |
20% |
| Novartis |
Cosentyx |
10% |
5. Revenue Trends
- In 2022, Otezla generated approximately USD 2.5 billion globally (Amgen Annual Report).
- Revenue growth has stabilized, reflecting market saturation and competition.
Price Structure and Trends
1. List Price
- U.S. average wholesale price (AWP): approximately USD 18,000 annually per patient (per 30-day supply).
- Price varies by dosage and formulation.
2. Insurance and Rebates
- Net prices are lower due to rebates, discounts, and pharmacy benefit manager negotiations.
- Exact net prices are confidential but approximate discounts range from 20–30%.
3. Price Trends
- List prices have increased modestly over the past five years (~3-5% annually).
- Patent protections ensure pricing stability through at least 2028.
Patent and Regulatory Landscape
- Patent protection valid until at least 2028, with filings extending into 2030s for certain formulations and indications (Amgen, 2019 patent filings).
- No immediate generic or biosimilar competition expected before patent expiry.
Price Projections (2024-2028)
| Year |
List Price (USD/year) |
Expected Market Penetration (%) |
Estimated Revenue (USD billions) |
Key Assumptions |
| 2024 |
18,000 |
30 |
2.7 |
Slight market growth, stable price environment |
| 2025 |
18,540 |
32 |
3.0 |
Market expansion, price increase per inflation |
| 2026 |
19,095 |
33 |
3.2 |
Slight price increase, rising adoption |
| 2027 |
19,668 |
34 |
3.4 |
Continued market growth, patent protections intact |
| 2028 |
20,258 |
35 |
3.5 |
Price stabilization, limited competition |
Note: These projections assume no major regulatory changes, patent extensions, or biosimilar entries. Price increases are aligned with historical trends and inflation.
Key Takeaways
- Market positioning for NDC 21922-0052 (Otezla) centers on its oral administration in psoriasis and psoriatic arthritis, with stable but mature market shares.
- Revenue and pricing will trend upward modestly until patent expiration expected around 2028, after which generic competition could sharply reduce prices.
- Competitive landscape favors biologics; Otezla's growth depends on expanding indications and improving formulary access.
- Price projections suggest an approximate USD 20,000 annual list price by 2028, with revenues near USD 3.5 billion domestically and globally.
FAQs
1. What factors could impact Otezla’s market share over the next five years?
Patent expiration, biologic innovation, shifts in payer preference, and regulatory approval of competitors influence market share.
2. How does Otezla’s pricing compare to biologics?
Otezla’s list price (~USD 18,000 annually) is lower than biologics (USD 30,000+ annually) but may have different efficacy profiles.
3. What are potential future markets for Otezla?
Emerging indications such as hidradenitis suppurativa and Crohn’s disease are under evaluation, presenting new revenue streams.
4. How do insurance negotiations affect net prices?
Rebates and discounts lower actual transaction prices by roughly 20–30%, affecting revenue projections.
5. What are the risks for investors regarding Otezla’s future?
Patent challenges, biosimilar entry, and regulatory restrictions are primary risks potentially impacting revenue and pricing.
References
[1] Amgen. (2022). Annual Report.
[2] Grand View Research. (2022). Psoriasis Market Size.
[3] IMS Health. (2023). Average Wholesale Price Data.
[4] FDA. (2021). Drug Approval and Patent Database.
